Welcome to Seminar on Optimal Nutrition Support to Cancer Patients Meera Kaur, PhD, RD. [email protected] 1 KILDONAN MEDICAL CENTRE

Welcome to Seminar on

Optimal Nutrition Support to Cancer Patients

Meera Kaur, PhD, RD.

[email protected]

1

KILDONAN MEDICAL CENTRE

Outline of the Session• Motivation for this Study • Objectives• The concept• The food development• Clinical outcome

– Materials and methods– Results and discussion

• Implications for the healthcare professionals• Summary and conclusion• References• Acknowledgement

Meera Kaur, PhD, RD

2


3

Meera Kaur, PhD, RD

Motivation for this research • Approximately 50 % of hospitalized cancer

patients are malnourished.

• Effective nutritional support to cancer patients is particularly challenging in developing countries due to the high cost of proprietary enteral formulae.

• Hence, the objectives of this study were ….


Objectives of the studyTo:• develop natural ingredient-based, low- cost

enteral food (LCEF) for cancer patients

• determine physicochemical and nutritional properties

• evaluate clinical outcome in cancer patients

Meera Kaur, PhD, RD

4


The concept

• Improving the bioavailability of nutrients in natural ingredients by suitable processing

• Modifying the texture of natural ingredients to suit enteral tube or oral feeding

• Enhancing with synbiotics and conditionally essential nutrients

Meera Kaur, PhD, RD

5


The process for LCEF (patented)6

Meera Kaur, PhD, RD

MaltedCereals

MaltedMung Bean

Toasted Soy

Mixing Cooking Homogenizing Spray drying Fortification

Vegetable/fish oil

Milk + LAB

PoppedAmaranth


LCEF

Nutritional information

Form Powder % of cal.Moisture (g%) 2.1Protein (g%) 22 19-20Fat (g%)-4 g fish oil 16 30-31Available Carbohydrate (g%) 56 49-50 Energy (Kcal/100g) 456Vitamins+minerals (g%) 2.5Total dietary fiber (g%) 5.0Soluble dietary fiber (g%) 2.3Insoluble dietary fiber 2.7Calcium (mg%) 300Phosphorous (mg%) 314LAB (cfu/g) 5.4×106

BCAA (g/100g of protein) 13.31(2.9g/100g food)L-Glutamine (g%) 4.0

7

Meera Kaur, PhD, RDKILDONAN MEDICAL CENTRE

Clinical Outcome inCancer Patients

8


Materials and Methods

9

Meera Kaur, PhD, RD


Patients’ characteristics...Characteristics Experimental Control

(n=32) (n=31)

Gender ratio (M/F) 19/13 17/14

Age (years)* 51.8±7.4 53.7±7.7

BMI (kg/m2)* 17.6±3.4 17.4±4.6

Usual wt (kg)* 66.1±2.4 65.8±3.7

Wt. loss at admission(%)* 7.1±3.6 7.3±1.8

Performance Status (Zubrod) 2.1±0.6 2.1±0.7

*Values are mean±SD

10


Patients’ characteristics• Type of Cancer:

• Treatment Received:

• Exclusion Criteria:

Inoperable Carcinoma Esophagus (Stage III or IV with no prior treatment)

Radiation and/or Chemotherapy

Pediatric patients, pregnant and nursing mothers

Meera Kaur, PhD, RD


11

Nutritional Support• Feeding mode: BolusTube feeding

• Energy requirement: Herris-Benedict Equation

• Protein requirement: 1.5-2.0g /Kg/day

• Initiation of feeding: Within 24 of admission

• Feeding duration: Till Discharge (45-60 days)

• Additional nutrients L-glutamine, Fish oil,

in experimental diet: Lactic acid bacteria (LAB)

• Control diet: Isocaloric, Isonitrogenous

proprietary enteral formula

,

12

Meera Kaur, PhD, RD


Outcome measures

• Tolerance

• Calorie intake

• Anthropometric indices

• Biochemical indices

13

Meera Kaur, PhD, RD

• Liver function tests

• Infectious episodes

• Test for lactose intolerance

• Length of hospital stay


Results

14


Energy Estimated and Intake

15

Meera Kaur, PhD, RD

Energy Estimated and Intake

0

500

1000

1500

2000

2500

3000

1 2 3 4 5 6 7 8Week

Kc

al

E-EST E-INT C-EST C-INT


Changes in body weight

16

Meera Kaur, PhD, RD

Changes in Body Weight

52

54

56

58

60

62

1 2 3 4 5 6 7 8Week

Wei

ght (

kg)

EXPT

CONT

Percent Loss of Body Wt.

0

2

4

6

8

Expt. Cont

(%)


Anthropometrical indices of patients Parameters Control Experimental C Vs E

I T I T p <

TSF (mm) 8.311.4 7.861.0 10.51.1 10.32.01 0.05

MAC( cm) 20.01.2 19.81.3 20.31.9 19.91.3 NS

MAMC (cm) 19.761.9 19.362.0 21.11.21 21.11.09 0.05

I=At the initiation of study; T=At the termination of study; NS=not significantValues are mean ±SD

17


Biochemical Indices of Patients Parameters Control Experimental C Vs E

I T I T P <

T. Protein (g%) 6.91.3 6.40.7 7.11.1 7.50.6 0.05

Albumin (g%) 4.1±0.3 3.1±0.6 3.80.4 4.70.5 0.05

Globulin (g%) 3.40.8 3.70.9 3.81.4 2.80.4 0.05

A/G 1.30.5 0.870.13 1.00.3 1.60.2 0.05

Alkaline 11.57.7 11.03.2 12.813.5 5.83.6 0.05

Phosphatase (Unit %)

SGPT (unit/ml) 208129.9 100.313.2 198.3135.7 44.711.1 0.05 I=At the initiation of study; T=At the termination of study; Values are mean ±SD

18


Infectious episodesCommonly isolated organisms

Staphylococcus Coagulase negative Staphylococcus aureasStreptococcus pneumoniae Stenotrophomonas maltophilia

Number of infectious episodesControl: 5.3±2.3Experimental: 3.2±0.8C Vs E: p<0.05

19


Other parameters• Tolerance of the feed: Well tolerated• Presence of lactose in stool: Nil • Length of hospital stay (days):

Experimental (E): 52.4±1.4

Control(C): 63.3±0.78

C Vs E: p<0.05• Cost of nutrition support/day:

Experimental (E): $3-5

Control(C): $10-15

C Vs E: p<0.05

20


Discussion

21


Discussion…Use of Glutamine in cancer patients:

Evidence of positive outcome

Oguz et al. (2007): colorectal cancer post operative complication & hospital stay

Ziegler (2001): cancer, BMT N2, infection, mucositis ,

hospital stay

Shewchuk et al. (1997): Morris Hepatoma 7777 tumor-directed natural killer cytotoxic activity or faster response to an immune

challenge.

22


Discussion…Use of fish oil in cancer patients:

Evidence of significant positive outcome

Christopher & Wigmore (2005): cancer wt. Gain, prevent cachexia

Barber (2001): pancreatic cancer lean tissue, reverse

cachexia

Barber et al. (1999): pancreatic cancer acute-phase protein response (APPR)

and wasting

23


Discussion…

Use of Branched-Chain Amino Acids (BCAA) in cancer patients: Evidence of significant positive outcome

Choudry et al. (2006): advanced cancer improves skeletal protein & quality of life

Okada (1988): gastric cancer (173 patients) improves metabolism and maintain good nitrogen retention

24


Discussion…

Use of Lactic Acid Bacteria (LAB) in cancer patients: Evidence of significant positive outcome

Rafter (2002): cancer enhances the host's immune response, produces

antimutagenic compounds

Hirayama & Rafter (2004): cancer improves immune system

25


DiscussionUse of synbiotics (LAB+plant fibre):

Evidence of significant positive outcomeBengmark (2006): Pancreatitis, trauma immunoparalysisBengmark (2005): Critically ill pathogens (c. diff)Bengmark (2005): Clinical Medicine reinforce immune

systemRayes et al. (2005): Liver transplant bacterial infection rateBengmark (2003) : Critically ill research limited, but great

hope for future; confirmed for LABOlah et al. (2002 ): Acute pancreatitis pancreatic sepsis,

no.of surgical interventions

26


Implications for the Practitioners• Dietary intervention for the restoration of general

health and nutritional status• Dietary management of drug-related complications• Foods rich in natural stimulants and protectants

may be considered for the management of GI functions and over all health

• Whenever possible and applicable, foods rich in synbiotics may be included in the diet of patients to improve liver function and promote gut health

• Team approach and adjunctive therapy help provide optimal nutrition support

27


Summary• Approximately 50% of hospitalized cancer patients are

malnourished. Nutrition support to cancer patients in developing countries is particularly challenging because of the high cost of proprietary formulae.

• Optimal nutritional support to cancer patients is important for effective medical treatment and overall clinical outcome.

• Research findings indicate that glutamine, fish oil, BCAA and LAB are anabolic and immunomodulatory nutrients in the nutritional support for cancer patients.

• In this study, a low-cost natural ingredient-based enteral food containing glutamine, fish oil, BCAA and LAB shows better clinical outcome in cancer patients than a proprietary defined-ingredient-based enteral food. Also, it is cost-effective.

• Further research is necessary to establish the role of specific nutrients for optimal nutritional support in cancer patients.

28


Conclusion• This study reveals the clinical efficacy of the LCEF

in cancer patients.

• LCEF is cost-effective and provides optimal nutritional support to the cancer patients.

• Development of the low-cost enteral foods contributes to patient care, particularly in developing countries where poverty is prevalent.

29


ReferencesOguz M., Kerem M., Bedirli A., Mentes, B B., Sakrak O., Salman B., H.

Bostanci. (2007),” L-Alanin L-glutamine supplementation improves the outcome

after colorectal surgery for cancer”, Colorectal Disease. 9 (6): 515 - 520. Bengmark, S. (2006), “Aggressive management of surgical emergencies,” Ann Roy

Coll Sur of Engl 88(7): 624-629. Choudry, HA., Pan, M., Karinch, AM., Souba WW. (2006), “Branched-Chain Amino

Acid-enriched nutritional support in surgical and cancer patients”, J Nutr: 136: 314S-318S.

Bengmark, S.(2005), “Synbiotics and the mucosal barrier in critically ill patients”, Curr opi gastro 21(6): 712-716.

Bengmark, S. and Martindale R. (2005), “Prebiotics and synbiotics in clinical medicine”, Nutr Cli Prac 20(2): 244-261.

Christopher, D., Stephen, WJ. (2005), “Systemic inflammation, cachexia and prognosis in patients with cancer. Anabolic and catabolic signals”, Cur Opi Clin

Nutr & Met Care. 8(3): 265-269.

30


ReferencesRayes N., Seehofer D. and Theruvath T. (2005), “Supply of pre- and probiotics

reduces bacterial infection rates after liver transplantation - A randomized, double-blind trial”, Am J Trans 5(1): 125-130.

Hirayama, K., Rafter, J. (2004), “The role of lactic acid bacteria in colon cancer prevention: mechanistic considerations”, Antonie van Leeuwenhoek (November): 391-394.

Olah A., Belagyi T., Issekutz A., Gamal M E. and Bengmark S. (2002), “Randomized clinical trial of specific lactobacillus and fibre supplement to early enteral nutrition in patients with acute pancreatitis”,The Brit J Sur 89(9): 1103-1107

Rafter, J. (2002), “Lactic acid bacteria and cancer: mechanistic perspective”, Brit J Nutr: 88 (Supplement, September): 89-94

Barber, MD. (2001), “Cancer cachexia and its treatment with fish-oil-enriched nutritional supplementation”, Nutr: (September): 751-755

31


ReferencesZiegler, T R. (2001), “Glutamine supplementation in cancer patients

receiving bone marrow transplantation and high dose chemotherapy”, J Nutr: 131: 2578S-2584S.

Barber, MD., Ross, JA., Preston T., Shenkin A., Fearon KCH. (1999), “Fish oil–enriched nutritional supplement attenuates progression of the acute-phase response in weight-losing patients with advanced pancreatic cancer” J Nutr: 12(4): 1120-1125.

Shewchuk, LD ., Baracos, VE., Field, CJ. (1997), “Dietary l-glutamine supplementation reduces the growth of the morris hepatoma 7777 in exercise-

trained and sedentary rats”, J Nutr: 127(1): 158-166. Okada, A., Mori, S., Totsuka, M., Okamoto, K., Usui, S., Fujita, H., Itakura, T. and

Mizote. H. (1988), “Branched-chain amino acids metabolic support in surgical patients: a randomized, controlled trial in patients with subtotal or total gastrectomy in 16 Japanese institutions” JPEN 12(4): 332-337.

32


AcknowledgementI gratefully acknowledge:

• The financial support provided by the Council of Scientific and Industrial Research (CSIR), Government of India, New Delhi, India.

• Dr. A. Anantha , MD, DMRE and S. Taramani, RD, Kidwai Memorial Institute of Oncology, Bangalore, India, for their support while conducting the clinical trial.

33


Thank you for gracing the session!

Any question?

34


Natural Vs Defined ingredient-based formulaNatural ingredient-based Defined- ingredient-based Carb: cereals and millets glucose,fructose,

maltodextrin,etc.

Protein: milk, legumes, etc. peptides, amino acids, etc.

Fat: edible oils fatty acids, MCT, triglycerides, etc.

Fibre: naturally present externally added

Flavor: need not to add must be added to mask off flavor of defined sources

Color: need not to add added to enhance acceptability

Osmolality: desirable range usually high

Efficacy: more physiological less physiological

Cost: less expensive more expensive


Documents

Welcome to Seminar on Optimal Nutrition Support to Cancer Patients Meera Kaur, PhD, RD. [email protected] 1 KILDONAN MEDICAL CENTRE